Method for detecting the susceptibility to develop adverse side effects related to bioimplants
AssigneeFundació Hospital Universitari Vall D'Hebron—Institut De Recerca
InventorsSimón Schwartz Navarro, Jaume Alijotas Reig
Life of this patent
Estimating the term…
Abstract
An in vitro method for the analysis of the genetic predisposition of an individual to develop adverse effects related to non-metallic materials implanted into the body. The method comprises determining if in a biological sample from an individual there is/are present the antigen/s HLA-B*08 and/or HLA-DRB1*03 of the major histocompatibility complex. The use of a kit for carrying out the determination and the use of the antigens as genetic markers is also disclosed.
Claims17
A method for determining predisposition of an individual to develop adverse effects related to non-metallic bioimplants implanted into the body of said individual, said method comprising:
- determining the presence of the major histocompatibility complex (MHC) HLA-B*08 and/or HLA-DRB1*03, by:
- (a) contacting a biological sample obtained from an individual with an antibody to determine the presence of an antigen of the major histocompatibility complex (MHC) HLA-B*08, HLA-DRB1*03, or a combination thereof, wherein the presence of the antigen of the MHC HLA-B*08, HLA-DRB1*03, or a combination thereof is an indication that said individual is predisposed to develop adverse effects related to non-metallic bioimplants;
- or
- (b) (i) obtaining a genetic material from a biological sample from said individual, and
- (ii) genotyping the obtained genetic material,
- wherein the presence of one or more alleles of the major histocompatibility complex (MHC) HLA-B*08, HLA-DRB1*03, or a combination thereof is an indication that said individual is predisposed to develop adverse effects related to non-metallic bioimplants.
(canceled)
A screening method comprising:
- (a) contacting a biological sample obtained from an individual with an antibody to determine the presence of an antigen of the major histocompatibility complex (MHC) HLA-B*08, HLA-DRB1*03, or a combination thereof, wherein the presence of the antigen of the MHC HLA-B*08, HLA-DRB1*03, or a combination thereof is an indication that said individual is predisposed to develop adverse effects related to non-metallic bioimplants;
- or
- (b) (i) obtaining a genetic material from a biological sample from an individual, and
- (ii) genotyping the obtained genetic material, and determining the presence of the major histocompatibility complex (MHC) HLA-B*08, HLA-DRB1*03, or a combination thereof;
- and,
- using the presence of the MHC HLA-B*08 and/or HLA-DRB1*03, or a combination thereof as a marker for the determination of a predisposition of an individual to develop adverse effects related to non-metallic bioimplants implanted into the body.
Dependencies are inferred from the claim text.